CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. […***…] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...Collaboration and Cross License Agreement • April 3rd, 2017 • Zymeworks Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AND CROSS LICENSE AGREEMENT (the “Agreement”), effective as of , 2016 (the “Effective Date”), by and between DAIICHI SANKYO CO., LTD., a corporation organized and existing under the laws of Japan, with its principal business office located at 3-5-1, Nihonbashi honcho, Chuo-ku, Tokyo, 103-8426, Japan (“DS”) and ZYMEWORKS INC., a corporation organized and existing under the laws of Canada, and extra provincially in British Columbia, having an address at 540-1385 West 8th Avenue, Vancouver, BC, Canada V6H 3V9 (“Zymeworks”). Zymeworks and DS are each referred to individually as a “Party” and together as the “Parties”.
SECOND AMENDMENT TO COLLABORATION AND CROSS LICENSE AGREEMENTCollaboration and Cross License Agreement • August 4th, 2021 • Zymeworks Inc. • Pharmaceutical preparations • New York
This Second Amendment (the “2nd Amendment”) to that certain Collaboration and Cross License Agreement, dated September 26, 2016, as amended pursuant to a Side Letter Agreement dated effective September 25, 2018 (collectively, the “Agreement”) by and between DAIICHI SANKYO COMPANY, LIMITED, a corporation organized and existing under the laws of Japan, with its principal business office located at 3-5-1, Nihonbashi honcho, Chuo-ku, Tokyo 103-8426, Japan (“DS”) and ZYMEWORKS INC., a corporation organized and existing under the laws of British Columbia, having an address at 540-1385 West 8th Avenue, Vancouver, BC, Canada V6H 3V9 (“Zymeworks”), is entered into as of July 2, 2021 (“2nd Amendment Effective Date”). Zymeworks and DS are each referred to individually as a “Party” and together as the “Parties.”
